Beactica Therapeutics AB, the Swedish precision oncology company, today announced the selection of BEA-17 as a preclinical candidate for its LSD1 programme aimed at finding new therapies for aggressive brain tumours and other life-threatening cancers.
BEA-17 is a first-in-class small molecule which has shown promising potentiation of immune-modulating treatments in preclinical models of several cancer forms. BEA-17 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of glioblastoma (GBM), the most aggressive form of brain tumour. With the selection of this first preclinical candidate, IND-enabling toxicology studies will be initiated in preparation for clinical trials.
“We are thrilled to announce the selection of BEA-17 as a preclinical candidate. Reaching this remarkable milestone is a major achievement, as the vast majority of programmes fail at the preclinical stage.” said Dr Per Källblad, CEO of Beactica Therapeutics. “The selection of this molecule reflects our aim to test this new approach in humans as quickly as possible.”